myriad_S_stacked.png
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
February 27, 2024 16:05 ET | Myriad Genetics, Inc.
Highlights: Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume.Full-year 2023 revenue of $753 million, grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek),...
myriad_S_stacked.png
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024 09:15 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National...
myriad_S_stacked.png
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on...
Reed_Dallas
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD,...
myriad_S_stacked.png
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024 09:25 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has completed the acquisition from...
myriad_S_stacked.png
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024 17:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr.,...
myriad_S_stacked.png
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024 18:10 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive...
myriad_S_stacked.png
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of...
myriad_S_stacked.png
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the...
ScottLeffler
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 21, 2023 08:30 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief...